Sunday 04 June 2023 - 23:36
NOTE: all of our usual telephone and FAX systems are currently down due to a dispute between our landlord and Verizon. We are working to remedy this situation and get our phones back on ASAP.
In the meantime, please use this mobile phone number: 978-715-9327, and this fax number: 781-491-0695.
Thank you for your patience as we work through this unfortunate outage caused by a dispute beyond our control.
Sale: 25% Off !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only - Limited Time Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
A-2300 Alectinib, Free Base, >99%
Synonyms : [AF802] [CH5424802]
Related Terms : [Alecensa]

- Size
- US $
- €
- £
- ¥
- 25 mg
- 49
- 45
- 39
- 6,900
- In stock
- 50 mg
- 63
- 58
- 50
- 8,800
- In stock
- 100 mg
- 92
- 85
- 73
- 12,900
- In stock
- 200 mg
- 139
- 129
- 111
- 19,500
- In stock
- 250 mg
- 161
- 150
- 129
- 22,500
- In stock
- 500 mg
- 259
- 241
- 207
- 36,300
- In stock
- 1 g
- 378
- 352
- 303
- 52,900
- In stock
- 2 g
- 684
- 637
- 549
- 95,700
- In stock
- 5 g
- 1,240
- 1,155
- 995
- 173,600
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 482.62
- C30H34N4O2
- [1256580-46-7]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO.
- Alectinib, also known as CH 5424802, is a potent, selective, and orally available ALK inhibitor (IC50 = 1.9 nM) and has weak or no inhibition against 24 other tested protein kinases. It has selective antitumor activity against cancers with ALK gene alterations, including non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo. It also blocked ALK L1196M, which corresponds to the gatekeeper mutation giving common resistance to kinase inhibitors, and prevented EML4-ALK L1196M-driven cell growth. Sakamoto H., et al. "CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant." Cancer Cell 19: 679-690 (2011).
- Alectinib reduced the tumor size in EML4-ALK-positive xenograft tumors that was not able to regress fully during treatment with crizotinib. Alectinib also inhibited the growth of some EML4-ALK mutant-driven tumors, such as the G1269A model. Kodama T., et al. "Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance." Cancer Lett. 351: 215-221 (2014).
- Two ALK mutations, a V1180L gatekeeper mutation from the cell line model and I1171T mutation from a patient, were found to develop resistance to alectinib and to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Katayama R., et al. "Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib." Clin. Cancer Res. 20: 5686-5696 (2014).
- This research compound is the free base form of alectinib. We also offer the Hydrochloride salt form of alectinib: Cat. No. A-2311, Alectinib,Hydrochloride Salt.
- This alectinib product is the free base whose CAS number is given above. The CAS number of the hydrochloride salt form is 1256589-74-8.
- Related CAS numbers: 1256589-74-8 for the hydrochloride salt (1:1); 1256590-18-7 for the hydrochloride salt, equivalent ratio not specified; 1358953-69-1 for the methanesulfonate salt, equivalent ratio not specified; 1820744-87-3 for the hydrochloride hydrate salt (1:1:1).
- Another CAS number previously assigned to Alectinib, namely 1416163-60-4, has been deleted by CAS and is no longer in use.
- Alectinib, free base is the active ingredient in the drug product sold under the trade name Alecensa®. This drug is currently approved in at least one country for use in patients with anaplastic lymphoma kinase -positive metastatic non-small cell lung cancer. NOTE: THE ALECTINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT ALECENSA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
